Recovering scientist turned early stage VC A biotech optimist fighting gravity

Public Pool Or Private Beach
February 23, 2015

Three years ago, I was walking across One Kendall Square in pursuit of a late lunch and bumped into a friend – another biotech CEO. I was a year into my role as CEO of Idenix, a publicly traded biotech

2 Comments

Better Living Through T-cells
February 19, 2015

Every week it feels like there’s yet another big event happening in the engineered T-cell therapy space. Recently it’s been biotech-pharma partnering (link). Before that it was the biggest biotech IPO of the year (link). And before that, it was

5 Comments

Data Snapshot: Dwarfed By Big Pharma, Biotech By The Numbers
February 16, 2015

Biotech fills the news these days – whether it’s the announcement of exciting new clinical data, another high-flying IPO, or a big M&A deal. Amidst the significant “share of voice” in the coverage of young and emerging biotech in the

1 Comment

Learnings From a Reluctant Entrepreneur
February 11, 2015

I am a scientist by vocation and training and an entrepreneur by accident.  I got into the business of starting companies when I decided almost a decade ago that I wanted to work on a new crazy therapeutic modality and the

1 Comment

Where Does All That Biotech Venture Capital Go?
February 9, 2015

Venture capital investing in biotech has long been hard to disaggregate: how much goes to “early stage” vs “late stage”, how much goes to CNS vs oncology, discovery vs Phase 3, etc… Today BIO’s David Thomas and Chad Wessel have

3 Comments

Data Snapshot: VC-Backed BioPharma M&A 2014
February 3, 2015

Similar to this time last year, when IPOs were capturing everyone’s attention, M&A in biotech has been delivering real value.  This morning HBM Partners released their outstanding report on BioPharma M&A in 2014 (here), and the conclusions are in line

Leave a comment

Infusing Biotech With Young Blood
January 30, 2015

This blog was written by Michael Gladstone, Principal at Atlas Venture, as part of the “From the Trenches” feature of LifeSciVC. Youth is often well represented among entrepreneurs – except in biotech. William Osler, founder of Johns Hopkins University and the

16 Comments

Venture-Backed Biotech Today: Reflections On Exits, Funding, and Startup Formation
January 22, 2015

Biotech is definitely red-hot, and has been for the past eight quarters. Immuno-oncology, cancer metabolism, gene therapy, orphan diseases, NASH, autoimmune – there’s a broad range of disease settings that are capturing the excitement and imagination of investors today. With some

4 Comments

Persistent Vitality At #JPM15
January 20, 2015

This blog was written by Kevin Pojasek, Founder and acting CEO of Quartet Medicine, as part of the “From the Trenches” feature of LifeSciVC. A favorite quote from the Jazz Age king that nicely captures life as a biotech entrepreneur.  Breaking

Leave a comment

Things I Expect To Hear At #JPM15
January 9, 2015

Are you ready for the circus?  Next week’s JPM Healthcare Conference is getting ready to kickoff, and much of the healthcare industry is feverishly preparing their materials for the mayhem. Given the biopharma industry pipeline’s exciting clinical progress, a record-breaking

Leave a comment

Immuno-Oncology: Scratching the Surface
January 8, 2015

Another day, another announcement about great data from immuno-oncology.  It’s clearly one of the hottest fields in biopharma today, and has been for a few years.  The opening paragraph of a recent Leerink report by Seamus Fernandez and team on

1 Comment

Rekindling The Flame
December 18, 2014

This blog was written by Mike Gilman, Atlas’ EIR and CEO of Padlock Therapeutics, as part of the “From the Trenches” feature of LifeSciVC. I thought I was done with immunology. I’m not formally trained as an immunologist, but I fell for it hard

3 Comments